News

A hormonal system that controls blood pressure was also seen to counter inflammatory processes in a mouse model of multiple sclerosis (MS) by influencing immune cells to take on a more anti-inflammatory profile. Researchers believe that it might be possible to manipulate the system with drugs, so as to boost anti-inflammatory…

A new ways of delivering drug therapies directly to the brain, overcoming the limitation imposed by the blood-brain barrier (a permeable barrier that protects the brain), has been discovered. The technique — which makes use of lipid bubbles and ultrasound — may pave the way for new treatments against neurological disorders,…

Data from the CARE-MS II clinical trial showed that Lemtrada (alemtuzumab) can lessen pre-existing disabilities in patients with relapsing-remitting multiple sclerosis (RRMS) who failed to respond adequately to previous disease-modifying therapies, according to a study of the trial’s data. The treatment was evaluated against Rebif (interferon beta-1a) therapy. The study, “Alemtuzumab…

The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report evaluating the comparative clinical effectiveness and value of disease-modifying therapies (DMTs) for patients with relapsing-remitting and primary-progressive forms of multiple sclerosis (MS). Through Dec. 21, patients, the public, and other stakeholders can access the 82-page report and…

A molecule secreted by a parasite was seen to prevent autoimmune reactions in a mouse model of multiple sclerosis (MS). As this molecule, a protein factor or peptide, also worked to prevent diabetes, researchers suggest it might be developed into a potential treatment for autoimmune diseases. The study, “A parasite-derived 68-mer peptide ameliorates…

Royal Philips recently announced the introduction of the IntelliSpace Portal 9.0, the latest edition of its advanced comprehensive visual analysis and quantification platform for neurological disorders. The platform was presented at the 2016 Radiological Society of North America Annual Meeting (RSNA), taking place through Dec. 2 in Chicago. Currently a work in…

Researchers have found a way to harness inflammation with the help of ultraviolet (UV) light, making it possible to design an anti-inflammatory treatment that is more specific and causes fewer side effects. If this approach can be developed for clinical treatment, it likely will have a large impact on the lives of people with…

The National Institutes of Health (NIH) awarded a $45,000 grant to a team of investigators, led by Tia Walker, PhD, at Indiana University Northwest, to support a research project into the role of copper in multiple sclerosis (MS). The award is a first for IU Northwest, and will allow the team to…

Palliative care helps to ease the symptoms of serious illnesses, providing people with cancer and those with other life-altering diseases, like multiple sclerosis (MS) or cystic fibrosis, a better quality of life, according to a study published in the Journal of the American Medical Association (JAMA). In the study, “Association Between Palliative Care And Patient…

A recent study published in Nature Communications showed, for the first time, that a protein complex called LUBAC is responsible for controlling the late-stage development of immune T-cells before they are released into the bloodstream. Several types of cells compose the immune system, working together to fight infections or cancer.

Dr. Rebecca Coll, a young researcher at the University of Queensland Institute of Molecular Bioscience, won the 2016 Research Australia Discovery Award for her work in identifying promising anti-inflammatory compounds that are able to block the NLRP3 inflammasome — a key driver of inflammation. The discovery could greatly benefit patients with inflammatory diseases,…

The Multiple Sclerosis Foundation, which is celebrating its 30th anniversary this year, has launched a new website to make access to information and services easier, and a newly designed MS Focus magazine. MS Focus magazine is the foundation’s publication dedicated to common challenges, solutions, and stories of the…

Magenta Therapeutics has completed its first round of financing, raising $48.5 million to develop ways of bringing bone marrow stem cell transplants to more patients with autoimmune diseases, such as multiple sclerosis (MS), among other illnesses. The new company aims to develop the first complete platform that can overcome the challenges in stem cell transplants,…

Discovery MS, a nonprofit research initiative based at the David H. Murdock Research Institute (DHMRI) in North Carolina, had its official launch recently, and announced a series of research projects into multiple sclerosis (MS). The initiative uses private funding to advance research aiming to develop new prognostic and diagnostic tools for MS.

AXIM Biotechnologies announced that the United States Patent and Trademark Office (USPTO) will be issuing a patent covering all cannabinoids — both natural and synthetic —  used in a chewing gum delivery system that may be included in its cannabinoid-containing, controlled-release chewing gum products. The USPTO has given the company a Notice of…

BAS Research, recently granted California’s first medicinal marijuana manufacturing and research license, is teaming with Montel Williams’ LenitivLabs startup to begin developing, producing and marketing medical-grade cannabis products. BAS’ goal is to replace the social stigma associated with cannabis by creating medical marijuana products with standardized dosing and proven efficacy. Its products are aimed at…

https://www.youtube.com/watch?v=JPa0bMG3zac In this film from MS Get Involved, Kerrie Newton talks about her exercise regimen and how important it is to her. She explains that exercising each day allows her to be able to stand for short periods and how it makes her feel better emotionally and helps with…

Quanterix and UmanDiagnostics are working to advance an assay capable of detecting neuron damage in a blood sample — a tool that could aid in the early diagnosis of multiple sclerosis (MS) and other neurodegenerative conditions. The collaboration brings Quanterix’ Simoa technology together with Uman’s antibodies against neurofilament light (Nf-L) — a…

In a cross-sectional study, researchers found that sexual dysfunction in patients with multiple sclerosis (MS) is linked to fatigue and depression. Treating these factors and identifying their causes is a potential strategy to treat the problem. The study, “Sexual function in multiple sclerosis and associations with demographic, disease…

Voters in four U.S. states on Nov. 8 chose to legalize the recreational use of marijuana, and those in three other states approved the medicinal use of cannabis — all gains for pharmaceutical and other companies designing cannabis-based therapies for people with long-term chronic ills whose symptoms might be helped with these…

Researchers have discovered that glial cells can also participate in pain sensation and enhance it in several disorders, including multiple sclerosis (MS). The study, “Gliogenic LTP spreads widely in nociceptive pathways,” was published in the journal Science. Our sensation of pain is processed in the brain…

Advances in brain imaging are making it possible to visualize early and ongoing events in multiple sclerosis (MS) — beginning with the first signs of inflammation caused by immune cells entering the brain. Should the new technique become available to physicians, it likely will not only allow for more precise diagnoses, but…

In general, patients with multiple sclerosis (MS) choose their disease-modifying drug (DMD) treatment based on considerations of effectiveness and potential side effects. But the weight they assign to these considerations can differ widely, making it important they are part of treatment decisions, especially regarding DMDs. These findings are in the report, “Identification and…

Despite recent studies showing that treatment with Ampyra (Fampyra in Europe; fampridine) improves both walking speed and ability, and offers psychological benefits to patients with multiple sclerosis (MS), the Scottish Medicines Consortium (SMC) recently decided to not recommend the drug for use on the National Health Service (NHS) in Scotland.